Trials / Terminated
TerminatedNCT02343549
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Wake Forest University Health Sciences · Academic / Other
- Sex
- All
- Age
- 22 Years
- Healthy volunteers
- Not accepted
Summary
All patients will complete best standard of care radiation, temozolomide and bevacizumab (6 weeks). Within two weeks of completion of this initial treatment period, study patients will be fitted with the NovoTTF-100A System and treated continuously. They will be treated with TTFields for 12 months for an average of 18 hours per day. The patient may elect to take a treatment break for a total of 3 days per month, for each month and still be in compliance. This will consist of wearing four electrically insulated electrode arrays on the head. The patients will also continue with maintenance temozolomide/ bevacizumab.
Detailed description
This study will be carried out in two stages. The first stage will enroll a cohort of 22 patients. The FDA will review safety data of the first 15 patients during enrollment of the first cohort. Enrollment and interim analysis of the first cohort of patients will be completed within 15 months of study commencement. Upon FDA approval and favorable interim analysis followed by subsequent protocol/consent amendment (as applicable), the second stage will enroll a cohort of 24 patients and will be completed within 15 months of stage 2 commencement. The overall duration of the study is expected to be no longer than 30 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | NovoTTF100A | |
| DRUG | Bevacizumab | |
| DRUG | Temozolomide |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2020-07-11
- Completion
- 2020-07-11
- First posted
- 2015-01-22
- Last updated
- 2022-11-03
- Results posted
- 2021-08-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02343549. Inclusion in this directory is not an endorsement.